Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wharton's jelly mesenchymal stem cells in fibrotic interstitial lung diseases
2024-514433-38-00Phase 2Authorised
- Sponsor
- Medical University of Gdańsk
- Start
- Nov 2024
- Countries
- 1
01
Overview
Phase 2 trial of allogeneic Wharton's jelly-derived mesenchymal stem cells in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF) (2 arms), sponsored by Medical University of Gdańsk. Planned start Nov 2024; status: authorised.
02
Drugs
allogeneic Wharton's jelly-derived mesenchymal stem cells
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2024-514433-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514433-38-00.